← All indications
HIV-Associated Lipodystrophy Syndrome
Defective metabolism leading to fat maldistribution in patients infected with HIV. The etiology appears to be multifactorial and probably involves some combination of infection-induced alterations in metabolism, direct effects of antiretroviral therapy, and patient-related factors.
Drugs by status
Approved for this indication (1)
Phase 4 trials (19)
Phase 3 trials (1)
Phase 2 trials (4)
Phase 1 trials (4)
Other trials (2)
Organizations
Organization Involved with Phase 4 Indications (16)
- Abbott
- Bristol-Myers Squibb
- Boehringer Ingelheim
- French National Agency for Research on AIDS and Viral Hepatitis
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Aarhus University
- Augusta University
- University of Southern Denmark
- Columbia University
- University of Copenhagen
- Leiden University
- University of Amsterdam
- University of Paris
- University of New South Wales
- The National Centre in HIV Epidemiology and Clinical Research, Sydney
Organization Involved with Phase 3 Indications (1)
Organization Involved with Phase 2 Indications (1)
Organization Involved with Phase 1 Indications (2)
Organization Involved with Other Experimental Indications (1)